Sichuan Baili Pharmaceutical Co., Ltd.: clinical-trial pipeline
Sichuan Baili Pharmaceutical Co., Ltd. is the sponsor of 140 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 135 are not yet finished and 8 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials135
Phase 2/3 and 335
Countries1
New in 90 days8
Trials by phase
| Phase | Trials |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 37 |
| Phase 3 | 27 |
| Phase 1/2 | 19 |
| Phase 2/3 | 8 |
| Not applicable | 1 |
| Phase 4 | 1 |
Trials by status
| Status | Trials |
|---|---|
| Recruiting | 79 |
| Active, not recruiting | 37 |
| Not yet recruiting | 19 |
| Unknown | 2 |
| Completed | 1 |
| Terminated | 1 |
| Withdrawn or not authorised | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 134 |
| Gastroenterology and liver | 16 |
| Nephrology and urology | 7 |
| Women's health and obstetrics | 5 |
| Haematology | 4 |
| Cardiovascular | 3 |
| Immunology and rheumatology | 2 |
| Metabolic and endocrine (diabetes, obesity) | 1 |
| Rare and genetic diseases | 1 |
Countries
| Country | Trials |
|---|---|
| China | 140 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-09-25 | New trial posted | A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Sol… |
| 2026-09-23 | New trial posted | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma… |
| 2026-09-18 | New trial posted | A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally A… |
| 2026-09-14 | New trial posted | A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large… |
| 2026-09-14 | New trial posted | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and… |
| 2026-09-01 | New trial posted | A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk L… |
| 2026-08-31 | New trial posted | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies a… |
| 2026-08-27 | New trial posted | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT06405425 | A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2 | Recruiting | China |
| NCT07279428 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid T… | Phase 1 | Recruiting | China |
| NCT06031584 | A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-… | Phase 1/2 | Recruiting | China |
| NCT07554456 | A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus… | Phase 2/3 | Recruiting | China |
| NCT06755242 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tu… | Phase 1 | Not yet recruiting | China |
| NCT07797881 | A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Naso… | Phase 2 | Not yet recruiting | China |
| NCT05022654 | SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. | Phase 2 | Active, not recruiting | China |
| NCT07739186 | A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Plat… | Phase 2/3 | Not yet recruiting | China |
| NCT05485753 | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and R… | Phase 1/2 | Active, not recruiting | China |
| NCT07769229 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Soli… | Phase 2 | Not yet recruiting | China |
| NCT05924750 | A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | China |
| NCT07744243 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors | Phase 1 | Not yet recruiting | China |
| NCT07642024 | A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Re… | Phase 2/3 | Recruiting | China |
| NCT06118333 | A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic N… | Phase 3 | Active, not recruiting | China |
| NCT07827261 | A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastati… | Phase 2 | Not yet recruiting | China |
| NCT05803018 | A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological M… | Phase 1/2 | Recruiting | China |
| NCT07753226 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | Phase 1 | Recruiting | China |
| NCT06008054 | A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced… | Phase 2 | Recruiting | China |
| NCT06787664 | A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma | Phase 2 | Active, not recruiting | China |
| NCT06475300 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell L… | Phase 2 | Recruiting | China |
| NCT07763652 | A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid… | Phase 1 | Recruiting | China |
| NCT05104775 | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy | Phase 1 | Active, not recruiting | China |
| NCT07793825 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid Tumors | Phase 1/2 | Not yet recruiting | China |
| NCT05020457 | SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. | Phase 2 | Active, not recruiting | China |
| NCT07255898 | A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignanci… | Phase 1 | Recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Sichuan Baili Pharmaceutical Co., Ltd. clinical trials: 135 open, 35 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/sichuan-baili-pharmaceutical-co-ltd/, data as of 2026-10-25.